Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus IRBESARTAN AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus IRBESARTAN AND HYDROCHLOROTHIAZIDE.
BENICAR HCT vs IRBESARTAN AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Irbesartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to AT1 receptors, inhibiting vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Oral: 1 tablet (irbesartan 150 mg / hydrochlorothiazide 12.5 mg or irbesartan 300 mg / hydrochlorothiazide 12.5 mg or irbesartan 300 mg / hydrochlorothiazide 25 mg) once daily, with or without food. Maximum: irbesartan 300 mg/hydrochlorothiazide 25 mg daily.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Irbesartan: 11-15 hours; Hydrochlorothiazide: 6-15 hours. Steady state achieved in 3-5 days.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Irbesartan: primarily biliary (80%) and renal (20%); Hydrochlorothiazide: renal (≥95% as unchanged drug).
Category C
Category D/X
ARB + Thiazide Diuretic
ARB